Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by Analysts

Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have earned a consensus recommendation of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $21.67.

Several equities research analysts have recently weighed in on RAPT shares. UBS Group reduced their price objective on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Wall Street Zen raised Rapt Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright raised their target price on Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. Finally, Lifesci Capital raised Rapt Therapeutics to a "strong-buy" rating and set a $31.00 target price for the company in a research report on Tuesday.

Institutional Investors Weigh In On Rapt Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Checkpoint Capital L.P. purchased a new stake in shares of Rapt Therapeutics during the 1st quarter worth about $134,000. AQR Capital Management LLC purchased a new stake in shares of Rapt Therapeutics during the 1st quarter worth about $188,000. ADAR1 Capital Management LLC raised its stake in shares of Rapt Therapeutics by 408.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock worth $7,284,000 after purchasing an additional 4,796,455 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Rapt Therapeutics by 303.1% during the 1st quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock worth $6,116,000 after purchasing an additional 3,769,414 shares in the last quarter. Finally, Comerica Bank raised its holdings in Rapt Therapeutics by 53.9% during the first quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares in the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

Rapt Therapeutics Price Performance

Shares of RAPT traded up $0.66 during trading hours on Wednesday, hitting $13.31. 66,312 shares of the company were exchanged, compared to its average volume of 130,058. The company has a market capitalization of $220.15 million, a PE ratio of -0.69 and a beta of -0.09. The firm has a fifty day simple moving average of $8.88 and a 200-day simple moving average of $8.72. Rapt Therapeutics has a one year low of $5.67 and a one year high of $27.84.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($2.48) by $1.84. Sell-side analysts expect that Rapt Therapeutics will post -2.14 EPS for the current year.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.